The Role of Men in Zika Prevention
Zika prevention efforts have primarily focused on infected mosquitos as the primary mode of transmission. Given the potential negative pregnancy outcomes of Zika, including congenital syndrome and microcephaly, pregnant women and women of reproductive age have been the focus of mosquito bite prevention efforts and messages.
Vacuna against Zika virus
A single-dose mRNA-based vaccine shows positive results in experimental pharmacology against zika, according to research published today in the journal Nature. We observed a rapid and lasting protective immunity without adverse events. We think this vaccine candidate is a promising strategy in the fight against the Zika virus, said Drew Weissman, lead author of the study.
Temperatures could accelerate the success of a Zika vaccine
As warmer temperatures herald annoying mosquitoes, the researchers are feverishly working on several promising vaccines against zika, a virus known to infect humans through the bite of this insect. The speed and debilitating effects of last year's zika outbreak in the Western Hemisphere generated a race to develop a vaccine. Just over a year after this pandemic was declared a global health emergency, a group of volunteers are undergoing preliminary testing.
Vaccine against zika is successful in mice
The successful results of the first tests of the vaccine can be tested this year in humans. A zika vaccine developed by researchers in Brazil and the United States was effective in tests with laboratory mice and could be tested this year in humans, Brazilian authorities said. The successful results of the first tests of the vaccine developed jointly by researchers from the University of Texas, the National Institute of Health of the United States and the Brazilian state center for health studies Institute Evandro Chagas, were highlighted Monday in a published article In the journal Nature Medicine.
New vaccine for Zika that is both effective and safe
Penn researchers have developed a first-of-its-kind vaccine to fight the Zika virus that demonstrates both safety and effectiveness. Participants in a clinical trial who received three doses of the GLS-5700 vaccine developed Zika-specific antibodies with minimal negative effects. These results open the door to future clinical trials and possible government approval for the vaccine. The study, which was published earlier this month in the New England Journal of Medicine, was a joint project of the Perelman School of Medicine, the Wistar Institute, Inovio Pharmaceuticals and GeneOne Life Science, Inc.